PT-141 (Research-Grade Peptide)

Bremelanotide analogue — for laboratory research only

Product Overview

PT-141, also known as bremelanotide, is a synthetic peptide developed as a
melanocortin receptor agonist. Unlike many peptides that act on the vascular system, PT-141
primarily targets the central melanocortin system. While bremelanotide is FDA-approved as
a prescription drug under the brand name Vyleesi® for a specific indication,
this version is provided strictly as a research-grade material for
laboratory investigation.

Research Highlights

• Melanocortin System Studies: PT-141 has been studied for its activity
  on melanocortin receptors (MC3R/MC4R) in the central nervous system.
  PubMed
• Preclinical Investigations: Animal studies have explored its role in
  sexual behavior and central neuroendocrine signaling.
  PubMed
• Clinical Research Context: Bremelanotide has undergone multiple human
  trials evaluating its pharmacology and safety profile.
  PubMed
• Ongoing Areas of Study: Laboratory research continues into
  melanocortin analogues and their potential roles in neurobiology and energy regulation.

Product Details & Handling

• Form: Lyophilized peptide powder, sterile vials
• Purity: ≥ 98% (Certificate of Analysis provided)
• Storage: Store at –20 °C; protect from light and moisture
• Handling: Laboratory use only with appropriate PPE;
  consult SDS for full safety guidance

Legal Disclaimer

This product is provided strictly for laboratory research use only.
It is not intended for human or veterinary consumption, therapeutic, diagnostic,
or clinical application. Customers are responsible for ensuring compliance with applicable
laws and institutional requirements. PT-141/bremelanotide is not approved by the FDA
in research form, and Windy City Peptide does not provide medical advice or support for human use.